Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment

Key Inclusion Criteria: * Diagnosis of advanced hepatocellular carcinoma * Asian ethnicity * Patient has failed ≥14 days of sorafenib treatment * Cirrhotic status of Child-Pugh Class A or B with a score of 7 * Eastern Cooperative Oncology Group performance status of 0, 1, or 2 * Life expectancy of at least 8 weeks * Adequate hematologic, hepatic, and renal function Key Exclusion Criteria: * Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy * Previous or concurrent cancer that is distinct in primary site * History of active cardiac disease * Thrombotic or embolic events within the past 6 months * Inability to swallow tablets or untreated malabsorption syndrome * History of HIV infection * Prior use of systemic investigational agents for hepatocellular carcinoma (except sorafenib)